Who are Nafcillin (or equivalent)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Semi-Synthetic Penicillin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nafcillin-or-equivalent.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Nafcillin (or equivalent) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nafcillin (or equivalent) (Nafcillin (or equivalent)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic (semi-synthetic penicillin). Area: Infectious Disease.

phase 3 Beta-lactam antibiotic (semi-synthetic penicillin) Penicillin-binding proteins (PBPs) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Nafcillin (or equivalent) (Nafcillin (or equivalent)) — Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Nafcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nafcillin (or equivalent) TARGET	Nafcillin (or equivalent)	Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	phase 3	Beta-lactam antibiotic (semi-synthetic penicillin)	Penicillin-binding proteins (PBPs)
Semi-Synthetic Penicillin	Semi-Synthetic Penicillin	Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	marketed	Beta-lactam antibiotic (semi-synthetic penicillin)	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic (semi-synthetic penicillin) class)

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nafcillin (or equivalent) — Competitive Intelligence Brief. https://druglandscape.com/ci/nafcillin-or-equivalent. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing